<code id='AD627D50A7'></code><style id='AD627D50A7'></style>
      • <acronym id='AD627D50A7'></acronym>
      <center id='AD627D50A7'><center id='AD627D50A7'><tfoot id='AD627D50A7'></tfoot></center><abbr id='AD627D50A7'><dir id='AD627D50A7'><tfoot id='AD627D50A7'></tfoot><noframes id='AD627D50A7'>
      • <optgroup id='AD627D50A7'><strike id='AD627D50A7'><sup id='AD627D50A7'></sup></strike><code id='AD627D50A7'></code></optgroup>
        5. <b id='AD627D50A7'><label id='AD627D50A7'><select id='AD627D50A7'><dt id='AD627D50A7'><span id='AD627D50A7'></span></dt></select></label></b><u id='AD627D50A7'></u>
          <i id='AD627D50A7'><strike id='AD627D50A7'><tt id='AD627D50A7'><pre id='AD627D50A7'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-09-28 04:40:45 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：3512
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Readout Newsletter: The latest on Novavax, Merck, Bluebird
                                
                            
          Next article：  
                                      
                                          Bright Health sells Medicare Advantage business to Molina
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles